{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T17:30:54Z","timestamp":1793035854350,"version":"4.5.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T00:00:00Z","timestamp":1720483200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T00:00:00Z","timestamp":1720483200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100001006","name":"Breast Cancer Research Foundation","doi-asserted-by":"publisher","award":["BCRF-083"],"award-info":[{"award-number":["BCRF-083"]}],"id":[{"id":"10.13039\/100001006","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001006","name":"Breast Cancer Research Foundation","doi-asserted-by":"publisher","award":["BCRF-083"],"award-info":[{"award-number":["BCRF-083"]}],"id":[{"id":"10.13039\/100001006","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001006","name":"Breast Cancer Research Foundation","doi-asserted-by":"publisher","award":["BCRF-083"],"award-info":[{"award-number":["BCRF-083"]}],"id":[{"id":"10.13039\/100001006","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001006","name":"Breast Cancer Research Foundation","doi-asserted-by":"publisher","award":["BCRF-083"],"award-info":[{"award-number":["BCRF-083"]}],"id":[{"id":"10.13039\/100001006","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001006","name":"Breast Cancer Research Foundation","doi-asserted-by":"publisher","award":["BCRF-083"],"award-info":[{"award-number":["BCRF-083"]}],"id":[{"id":"10.13039\/100001006","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001006","name":"Breast Cancer Research Foundation","doi-asserted-by":"publisher","award":["BCRF-083"],"award-info":[{"award-number":["BCRF-083"]}],"id":[{"id":"10.13039\/100001006","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NIH\/NCI","award":["1R01 CA220284"],"award-info":[{"award-number":["1R01 CA220284"]}]},{"name":"NIH\/NCI","award":["1R01 CA220284"],"award-info":[{"award-number":["1R01 CA220284"]}]},{"name":"NIH\/NCI","award":["1R01 CA220284"],"award-info":[{"award-number":["1R01 CA220284"]}]},{"name":"NIH\/NCI","award":["1R01 CA220284"],"award-info":[{"award-number":["1R01 CA220284"]}]},{"name":"NIH","award":["R01CA234025"],"award-info":[{"award-number":["R01CA234025"]}]},{"name":"NIH","award":["R01CA234025"],"award-info":[{"award-number":["R01CA234025"]}]},{"name":"The Julius and Mary Landfield Cancer Research Fund"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Cancer treatments often become ineffective because of acquired drug resistance. To characterize changes in breast cancer cells accompanying development of resistance to inhibitors of the oncogenic transcription factor, FOXM1, we investigated the suppression of cell death pathways, especially ferroptosis, in FOXM1 inhibitor-resistant cells. We also explored whether ferroptosis activators can synergize with FOXM1 inhibitors and can overcome FOXM1 inhibitor resistance.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In estrogen receptor-positive and triple-negative breast cancer cells treated with FOXM1 inhibitor NB73 and ferroptosis activators dihydroartemisinin and JKE1674, alone and in combination, we measured suppression of cell viability, motility, and colony formation, and monitored changes in gene and protein pathway expressions and mitochondrial integrity.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Growth suppression of breast cancer cells by FOXM1 inhibitors is accompanied by increased cell death and alterations in mitochondrial morphology and metabolic activity. Low doses of FOXM1 inhibitor strongly synergize with ferroptosis inducers to reduce cell viability, migration, colony formation, and expression of proliferation-related genes, and increase intracellular Fe<jats:sup>+2<\/jats:sup> and lipid peroxidation, markers of ferroptosis. Acquired resistance to FOXM1 inhibition is associated with increased expression of cancer stem-cell markers and proteins that repress ferroptosis, enabling cell survival and drug resistance. Notably, resistant cells are still sensitive to growth suppression by low doses of ferroptosis activators, effectively overcoming the acquired resistance.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Delineating changes in viability and cell death pathways that can overcome drug resistance should be helpful in determining approaches that might best prevent or reverse resistance to therapeutic targeting of FOXM1 and ultimately improve patient clinical outcomes.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10549-024-07420-9","type":"journal-article","created":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T05:01:50Z","timestamp":1720501310000},"page":"307-320","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Resistance to FOXM1 inhibitors in breast cancer is accompanied by impeding ferroptosis and apoptotic cell death"],"prefix":"10.1007","volume":"208","author":[{"given":"Sandeep","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Ziegler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blake N.","family":"Plotner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen M.","family":"Flatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Hoon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Katzenellenbogen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8847-2752","authenticated-orcid":false,"given":"Benita S.","family":"Katzenellenbogen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,9]]},"reference":[{"key":"7420_CR1","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1186\/s13058-014-0436-4","volume":"16","author":"A Bergamaschi","year":"2014","unstructured":"Bergamaschi A, Madak-Erdogan Z, Kim YJ, Choi YL, Lu H, Katzenellenbogen BS (2014) The forkhead transcription factor FOXM1 promotes endocrine resistance and invasiveness in estrogen receptor-positive breast cancer by expansion of stem-like cancer cells. Breast Cancer Res 16:436. https:\/\/doi.org\/10.1186\/s13058-014-0436-4","journal-title":"Breast Cancer Res"},{"key":"7420_CR2","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a041333","author":"S Goel","year":"2022","unstructured":"Goel S, Chandarlapaty S (2022) Emerging therapies for breast cancer. Cold Spring Harb Perspect Med. https:\/\/doi.org\/10.1101\/cshperspect.a041333","journal-title":"Cold Spring Harb Perspect Med"},{"key":"7420_CR3","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s13058-023-01665-w","volume":"251","author":"S Liu","year":"2023","unstructured":"Liu S, Xie SM, Liu W, Gagea M, Hanker AB, Nguyen N, Singareeka Raghavendra A, Yang-Kolodji G, Chu F, Neelapu SS et al (2023) Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment. Breast Cancer Res 251:62. https:\/\/doi.org\/10.1186\/s13058-023-01665-w","journal-title":"Breast Cancer Res"},{"key":"7420_CR4","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/978-3-031-33602-7_9","volume":"188","author":"A Marra","year":"2023","unstructured":"Marra A, Trapani D, Ferraro E, Curigliano G (2023) Mechanisms of endocrine resistance in hormone receptor-positive breast cancer. Cancer Treat Res 188:219\u2013235. https:\/\/doi.org\/10.1007\/978-3-031-33602-7_9","journal-title":"Cancer Treat Res"},{"key":"7420_CR5","doi-asserted-by":"publisher","first-page":"16198","DOI":"10.3390\/ijms242216198","volume":"24","author":"F Raheem","year":"2023","unstructured":"Raheem F, Karikalan SA, Batalini F, El Masry A, Mina L (2023) Metastatic ER+ Breast Cancer: Mechanisms of Resistance and Future Therapeutic Approaches. Int J Mol Sci 24:16198. https:\/\/doi.org\/10.3390\/ijms242216198","journal-title":"Int J Mol Sci"},{"key":"7420_CR6","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.ctrv.2016.08.008","volume":"50","author":"K Tryfonidis","year":"2016","unstructured":"Tryfonidis K, Zardavas D, Katzenellenbogen BS, Piccart M (2016) Endocrine treatment in breast cancer: cure, resistance and beyond. Cancer Treat Rev 50:68\u201381. https:\/\/doi.org\/10.1016\/j.ctrv.2016.08.008","journal-title":"Cancer Treat Rev"},{"key":"7420_CR7","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1001\/jama.2018.19323","volume":"321","author":"AG Waks","year":"2019","unstructured":"Waks AG, Winer EP (2019) Breast cancer treatment: a review. Jama 321:288\u2013300. https:\/\/doi.org\/10.1001\/jama.2018.19323","journal-title":"Jama"},{"key":"7420_CR8","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s10549-023-06878-3","volume":"198","author":"VS Guillen","year":"2023","unstructured":"Guillen VS, Ziegler Y, Gopinath C, Kumar S, Dey P, Plotner BN, Dawson NZ, Kim SH, Katzenellenbogen JA, Katzenellenbogen BS (2023) Effective combination treatments for breast cancer inhibition by FOXM1 inhibitors with other targeted cancer drugs. Breast Cancer Res Treat 198:607\u2013621. https:\/\/doi.org\/10.1007\/s10549-023-06878-3","journal-title":"Breast Cancer Res Treat"},{"key":"7420_CR9","doi-asserted-by":"publisher","first-page":"3899","DOI":"10.1038\/s41388-022-02398-4","volume":"41","author":"Y Cheng","year":"2022","unstructured":"Cheng Y, Sun F, Thornton K, Jing X, Dong J, Yun G, Pisano M, Zhan F, Kim SH, Katzenellenbogen JA et al (2022) FOXM1 regulates glycolysis and energy production in multiple myeloma. Oncogene 41:3899\u20133911. https:\/\/doi.org\/10.1038\/s41388-022-02398-4","journal-title":"Oncogene"},{"key":"7420_CR10","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.3390\/cancers12092677","volume":"12","author":"P Dey","year":"2020","unstructured":"Dey P, Wang A, Ziegler Y, Kim SH, El-Ashry D, Katzenellenbogen JA, Katzenellenbogen BS (2020) Suppression of tumor growth, metastasis, and signaling pathways by reducing FOXM1 activity in triple negative breast cancer. Cancers (Basel) 12:2677. https:\/\/doi.org\/10.3390\/cancers12092677","journal-title":"Cancers (Basel)"},{"key":"7420_CR11","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s13058-023-01675-8","volume":"25","author":"BS Katzenellenbogen","year":"2023","unstructured":"Katzenellenbogen BS, Guillen VS, Katzenellenbogen JA (2023) Targeting the oncogenic transcription factor FOXM1 to improve outcomes in all subtypes of breast cancer. Breast Cancer Res 25:76. https:\/\/doi.org\/10.1186\/s13058-023-01675-8","journal-title":"Breast Cancer Res"},{"key":"7420_CR12","doi-asserted-by":"publisher","DOI":"10.1172\/JCI162324","volume":"133","author":"I Nandi","year":"2023","unstructured":"Nandi I, Smith HW, Sanguin-Gendreau V, Ji L, Pacis A, Papavasiliou V, Zuo D, Nam S, Attalla SS, Kim SH et al (2023) Coordinated activation of c-Src and FOXM1 drives tumor cell proliferation and breast cancer progression. J Clin Invest 133:e162324. https:\/\/doi.org\/10.1172\/JCI162324","journal-title":"J Clin Invest"},{"key":"7420_CR13","doi-asserted-by":"publisher","first-page":"6282","DOI":"10.3390\/cancers13246282","volume":"13","author":"Y Ziegler","year":"2021","unstructured":"Ziegler Y, Guillen VS, Kim SH, Katzenellenbogen JA, Katzenellenbogen BS (2021) Transcription regulation and genome rewiring governing sensitivity and resistance to FOXM1 inhibition in breast cancer. Cancers (Basel) 13:6282. https:\/\/doi.org\/10.3390\/cancers13246282","journal-title":"Cancers (Basel)"},{"key":"7420_CR14","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41523-019-0141-7","volume":"5","author":"Y Ziegler","year":"2019","unstructured":"Ziegler Y, Laws MJ, Sanabria Guillen V, Kim SH, Dey P, Smith BP, Gong P, Bindman N, Zhao Y, Carlson K et al (2019) Suppression of FOXM1 activities and breast cancer growth in vitro and in vivo by a new class of compounds. NPJ Breast Cancer 5:45. https:\/\/doi.org\/10.1038\/s41523-019-0141-7","journal-title":"NPJ Breast Cancer"},{"key":"7420_CR15","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1038\/s41571-020-00462-0","volume":"185","author":"X Chen","year":"2021","unstructured":"Chen X, Kang R, Kroemer G, Tang D (2021) Broadening horizons: the role of ferroptosis in cancer. Nat Rev Clin Oncol 185:280\u2013296. https:\/\/doi.org\/10.1038\/s41571-020-00462-0","journal-title":"Nat Rev Clin Oncol"},{"key":"7420_CR16","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20210518","volume":"218","author":"X Chen","year":"2021","unstructured":"Chen X, Kang R, Kroemer G, Tang D (2021) Ferroptosis in infection, inflammation, and immunity. J Exp Med 218:e20210518. https:\/\/doi.org\/10.1084\/jem.20210518","journal-title":"J Exp Med"},{"key":"7420_CR17","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/s41580-020-00324-8","volume":"224","author":"X Jiang","year":"2021","unstructured":"Jiang X, Stockwell BR, Conrad M (2021) Ferroptosis: mechanisms, biology and role in disease. Nat Rev Mol Cell Biol 224:266\u2013282. https:\/\/doi.org\/10.1038\/s41580-020-00324-8","journal-title":"Nat Rev Mol Cell Biol"},{"key":"7420_CR18","doi-asserted-by":"publisher","first-page":"674","DOI":"10.3390\/cells8070674","volume":"8","author":"R Khandia","year":"2019","unstructured":"Khandia R, Dadar M, Munjal A, Dhama K, Karthik K, Tiwari R, Yatoo MI, Iqbal HMN, Singh KP, Joshi SK et al (2019) A Comprehensive review of autophagy and its various roles in infectious, non-infectious, and lifestyle diseases: current knowledge and prospects for disease prevention, novel drug design, and therapy. Cells 8:674. https:\/\/doi.org\/10.3390\/cells8070674","journal-title":"Cells"},{"key":"7420_CR19","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/s41568-022-00459-0","volume":"227","author":"G Lei","year":"2022","unstructured":"Lei G, Zhuang L, Gan B (2022) Targeting ferroptosis as a vulnerability in cancer. Nat Rev Cancer 227:381\u2013396. https:\/\/doi.org\/10.1038\/s41568-022-00459-0","journal-title":"Nat Rev Cancer"},{"key":"7420_CR20","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1016\/j.cell.2022.06.003","volume":"18514","author":"BR Stockwell","year":"2022","unstructured":"Stockwell BR (2022) Ferroptosis turns 10: emerging mechanisms, physiological functions, and therapeutic applications. Cell 18514:2401\u20132421. https:\/\/doi.org\/10.1016\/j.cell.2022.06.003","journal-title":"Cell"},{"key":"7420_CR21","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12943-022-01530-y","volume":"211","author":"C Zhang","year":"2022","unstructured":"Zhang C, Liu X, Jin S, Chen Y, Guo R (2022) Ferroptosis in cancer therapy: a novel approach to reversing drug resistance. Mol Cancer 211:47. https:\/\/doi.org\/10.1186\/s12943-022-01530-y","journal-title":"Mol Cancer"},{"key":"7420_CR22","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.cmet.2020.10.011","volume":"326","author":"J Zheng","year":"2020","unstructured":"Zheng J, Conrad M (2020) The metabolic underpinnings of ferroptosis. Cell Metab 326:920\u2013937. https:\/\/doi.org\/10.1016\/j.cmet.2020.10.011","journal-title":"Cell Metab"},{"key":"7420_CR23","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/msb.2013.28","volume":"9","author":"Z Madak-Erdogan","year":"2013","unstructured":"Madak-Erdogan Z, Charn TH, Jiang Y, Liu ET, Katzenellenbogen JA, Katzenellenbogen BS (2013) Integrative genomics of gene and metabolic regulation by estrogen receptors alpha and beta, and their coregulators. Mol Syst Biol 9:676. https:\/\/doi.org\/10.1038\/msb.2013.28","journal-title":"Mol Syst Biol"},{"key":"7420_CR24","doi-asserted-by":"publisher","first-page":"5602","DOI":"10.1158\/0008-5472.CAN-17-1265","volume":"7720","author":"Y Zhao","year":"2017","unstructured":"Zhao Y, Laws MJ, Guillen VS, Ziegler Y, Min J, Sharma A, Kim SH, Chu D, Park BH, Oesterreich S et al (2017) Structurally novel antiestrogens elicit differential responses from constitutively active mutant estrogen receptors in breast cancer cells and tumors. Cancer Res 7720:5602\u20135613. https:\/\/doi.org\/10.1158\/0008-5472.CAN-17-1265","journal-title":"Cancer Res"},{"key":"7420_CR25","first-page":"285","volume":"36","author":"S Loewe","year":"1953","unstructured":"Loewe S (1953) The problem of synergism and antagonism of combined drugs. Arzneimittelforschung 36:285\u2013290","journal-title":"Arzneimittelforschung"},{"key":"7420_CR26","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.csbj.2015.09.001","volume":"13","author":"B Yadav","year":"2015","unstructured":"Yadav B, Wennerberg K, Aittokallio T, Tang J (2015) Searching for drug synergy in complex dose-response landscapes using an interaction potency model. Comput Struct Biotechnol J 13:504\u2013513. https:\/\/doi.org\/10.1016\/j.csbj.2015.09.001","journal-title":"Comput Struct Biotechnol J"},{"key":"7420_CR27","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1177\/1087057114521867","volume":"195","author":"W Zhao","year":"2014","unstructured":"Zhao W, Sachsenmeier K, Zhang L, Sult E, Hollingsworth RE, Yang H (2014) A new bliss independence model to analyze drug combination data. J Biomol Screen 195:817\u2013821. https:\/\/doi.org\/10.1177\/1087057114521867","journal-title":"J Biomol Screen"},{"key":"7420_CR28","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.gpb.2022.01.004","volume":"203","author":"S Zheng","year":"2022","unstructured":"Zheng S, Wang W, Aldahdooh J, Malyutina A, Shadbahr T, Tanoli Z, Pessia A, Tang J (2022) SynergyFinder Plus: toward better interpretation and annotation of drug combination screening datasets. Genom Proteom Bioinfor 203:587\u2013596. https:\/\/doi.org\/10.1016\/j.gpb.2022.01.004","journal-title":"Genom Proteom Bioinfor"},{"key":"7420_CR29","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.3390\/ijms24021607","volume":"24","author":"M Chen","year":"2023","unstructured":"Chen M, Shi Z, Sun Y, Ning H, Gu X, Zhang L (2023) Prospects for anti-tumor mechanism and potential clinical application based on glutathione peroxidase 4 mediated ferroptosis. Int J Mol Sci 24:1607. https:\/\/doi.org\/10.3390\/ijms24021607","journal-title":"Int J Mol Sci"},{"key":"7420_CR30","doi-asserted-by":"publisher","first-page":"5566","DOI":"10.1074\/jbc.M114.606459","volume":"290","author":"BG Drew","year":"2014","unstructured":"Drew BG, Hamidi H, Zhou Z, Villanueva CJ, Krum SA, Calkin AC, Parks BW, Ribas V, Kalajian NY, Phun J et al (2014) ERalpha-regulated Lipocalin 2 expression in adipose tissue links obesity with breast cancer progression. J Biol Chem 290:5566\u20135581 https:\/\/doi.org\/10.1074\/jbc.M114.606459","journal-title":"J Biol Chem"},{"key":"7420_CR31","doi-asserted-by":"publisher","first-page":"8099","DOI":"10.2147\/OTT.S181223","volume":"11","author":"C Hu","year":"2018","unstructured":"Hu C, Yang K, Li M, Huang W, Zhang F, Wang H (2018) Lipocalin 2: a potential therapeutic target for breast cancer metastasis. Onco Targets Ther 11:8099\u20138106. https:\/\/doi.org\/10.2147\/OTT.S181223","journal-title":"Onco Targets Ther"},{"key":"7420_CR32","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s10142-023-01279-7","volume":"241","author":"J Jiang","year":"2023","unstructured":"Jiang J, Zhu J, Qiu P, Ni J, Zhu W, Wang X (2023) HNRNPA2B1-mediated m6A modification of FOXM1 promotes drug resistance and inhibits ferroptosis in endometrial cancer via regulation of LCN2. Funct Integr Genom 241:3. https:\/\/doi.org\/10.1007\/s10142-023-01279-7","journal-title":"Funct Integr Genom"},{"key":"7420_CR33","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/s41467-021-20904-2","volume":"121","author":"J Liu","year":"2021","unstructured":"Liu J, Song X, Kuang F, Zhang Q, Xie Y, Kang R, Kroemer G, Tang D (2021) NUPR1 is a critical repressor of ferroptosis. Nat Commun 121:647. https:\/\/doi.org\/10.1038\/s41467-021-20904-2","journal-title":"Nat Commun"},{"key":"7420_CR34","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3892\/ijo.2021.5201","volume":"58","author":"TA Martin","year":"2021","unstructured":"Martin TA, Li AX, Sanders AJ, Ye L, Frewer K, Hargest R, Jiang WG (2021) NUPR1 and its potential role in cancer and pathological conditions (Review). Int J Oncol 58:21. https:\/\/doi.org\/10.3892\/ijo.2021.5201","journal-title":"Int J Oncol"},{"key":"7420_CR35","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/s41419-021-03442-z","volume":"122","author":"L Wang","year":"2021","unstructured":"Wang L, Sun J, Yin Y, Sun Y, Ma J, Zhou R, Chang X, Li D, Yao Z, Tian S et al (2021) Transcriptional coregualtor NUPR1 maintains tamoxifen resistance in breast cancer cells. Cell Death Dis 122:149. https:\/\/doi.org\/10.1038\/s41419-021-03442-z","journal-title":"Cell Death Dis"},{"key":"7420_CR36","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3892\/ijo.2021.5257","volume":"59","author":"J Tang","year":"2021","unstructured":"Tang J, Li Y, Xia S, Li J, Yang Q, Ding K, Zhang H (2021) Sequestosome 1\/p62: A multitasker in the regulation of malignant tumor aggression (Review). Int J Oncol 59:77. https:\/\/doi.org\/10.3892\/ijo.2021.5257","journal-title":"Int J Oncol"},{"key":"7420_CR37","doi-asserted-by":"publisher","first-page":"5416923","DOI":"10.1155\/2018\/5416923","volume":"2018","author":"LTH Phi","year":"2018","unstructured":"Phi LTH, Sari IN, Yang YG, Lee SH, Jun N, Kim KS, Lee YK, Kwon HY (2018) Cancer stem cells (CSCs) in drug resistance and their therapeutic implications in cancer treatment. Stem Cells Int 2018:5416923. https:\/\/doi.org\/10.1155\/2018\/5416923","journal-title":"Stem Cells Int"},{"key":"7420_CR38","doi-asserted-by":"publisher","unstructured":"Sher G, Masoodi T, Patil K, Akhtar S, Kuttikrishnan S, Ahmad A, Uddin S (2022) Dysregulated FOXM1 signaling in the regulation of cancer stem cells. Semin Cancer Biol 86Pt 3:107\u2013121. https:\/\/doi.org\/10.1016\/j.semcancer.2022.07.009.","DOI":"10.1016\/j.semcancer.2022.07.009"},{"key":"7420_CR39","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"1445","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 1445:646\u2013674. https:\/\/doi.org\/10.1016\/j.cell.2011.02.013","journal-title":"Cell"},{"key":"7420_CR40","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.ccell.2020.03.009","volume":"374","author":"AB Hanker","year":"2020","unstructured":"Hanker AB, Sudhan DR, Arteaga CL (2020) Overcoming endocrine resistance in breast cancer. Cancer Cell 374:496\u2013513. https:\/\/doi.org\/10.1016\/j.ccell.2020.03.009","journal-title":"Cancer Cell"},{"key":"7420_CR41","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1002\/ijc.33711","volume":"1497","author":"N Chaudhary","year":"2021","unstructured":"Chaudhary N, Choudhary BS, Shah SG, Khapare N, Dwivedi N, Gaikwad A, Joshi N, Raichanna J, Basu S, Gurjar M et al (2021) Lipocalin 2 expression promotes tumor progression and therapy resistance by inhibiting ferroptosis in colorectal cancer. Int J Cancer 1497:1495\u20131511. https:\/\/doi.org\/10.1002\/ijc.33711","journal-title":"Int J Cancer"},{"key":"7420_CR42","doi-asserted-by":"publisher","first-page":"421","DOI":"10.2174\/156800908785133196","volume":"85","author":"DW Clark","year":"2008","unstructured":"Clark DW, Mitra A, Fillmore RA, Jiang WG, Samant RS, Fodstad O, Shevde LA (2008) NUPR1 interacts with p53, transcriptionally regulates p21 and rescues breast epithelial cells from doxorubicin-induced genotoxic stress. Curr Cancer Drug Targets 85:421\u2013430. https:\/\/doi.org\/10.2174\/156800908785133196","journal-title":"Curr Cancer Drug Targets"},{"key":"7420_CR43","doi-asserted-by":"publisher","first-page":"5234","DOI":"10.1158\/1078-0432.CCR-12-0026","volume":"1819","author":"T Hamidi","year":"2012","unstructured":"Hamidi T, Cano CE, Grasso D, Garcia MN, Sandi MJ, Calvo EL, Dagorn JC, Lomberk G, Urrutia R, Goruppi S et al (2012) Nupr1-aurora kinase A pathway provides protection against metabolic stress-mediated autophagic-associated cell death. Clin Cancer Res 1819:5234\u20135246. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-0026","journal-title":"Clin Cancer Res"},{"key":"7420_CR44","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1021\/acscentsci.6b00165","volume":"28","author":"RC Botham","year":"2016","unstructured":"Botham RC, Roth HS, Book AP, Roady PJ, Fan TM, Hergenrother PJ (2016) Small-molecule procaspase-3 activation sensitizes cancer to treatment with diverse chemotherapeutics. ACS Cent Sci 28:545\u2013559. https:\/\/doi.org\/10.1021\/acscentsci.6b00165","journal-title":"ACS Cent Sci"},{"key":"7420_CR45","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1158\/0008-5472.CAN-20-3477","volume":"81","author":"A Ghoochani","year":"2021","unstructured":"Ghoochani A, Hsu EC, Aslan M, Rice MA, Nguyen HM, Brooks JD, Corey E, Paulmurugan R, Stoyanova T (2021) Ferroptosis inducers are a novel therapeutic approach for advanced prostate cancer. Cancer Res 81:1583\u20131594. https:\/\/doi.org\/10.1158\/0008-5472.CAN-20-3477","journal-title":"Cancer Res"},{"key":"7420_CR46","doi-asserted-by":"publisher","first-page":"756","DOI":"10.3390\/cancers16040756","volume":"16","author":"N Merjaneh","year":"2024","unstructured":"Merjaneh N, Hajjar M, Lan YW, Kalinichenko VV, Kalin TV (2024) The promise of combination therapies with FOXM1 inhibitors for cancer treatment. Cancers (Basel) 16:756. https:\/\/doi.org\/10.3390\/cancers16040756","journal-title":"Cancers (Basel)"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-024-07420-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-024-07420-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-024-07420-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,5]],"date-time":"2024-10-05T21:02:58Z","timestamp":1728162178000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-024-07420-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,9]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["7420"],"URL":"https:\/\/doi.org\/10.1007\/s10549-024-07420-9","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,9]]},"assertion":[{"value":"11 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"BSK, JAK, and SHK are co-inventors on patents filed by the University of Illinois to cover the FOXM1 inhibitor compounds described in this paper. BSK and JAK are members of the Scientific Advisory Board of Celcuity. The other authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"This article does not contain any studies with human participants or involving animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}